US biotech major Amgen announced financial results for the second quarter of 2025 after market closed on Tuesday, with ...

The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...

A preclinical biotech company based in Wilmington, Delaware, focused on developing CAR‑T cell immunotherapies to treat severe ...

Pfizer posted second-quarter 2025 earnings and revenue that exceeded analyst estimates and raised its full-year profit ...

US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial ...

Japanese drugmaker Sumitomo Pharma Company and Tokyo-based Racthera announced that on August 5, they had submitted an ...

Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and ...

The UK’s National Health Service (NHS) and local authorities have started the rollout of world-first gonorrhoea vaccination ...

Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO).

Noom’s Microdose GLP-1Rx Program is priced at $119 to start, followed by $199 per month, which includes medication, if ...

Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local ...

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.